Biogen, Biovitrum advancing hemophilia drug

Posted In: Life Sciences

By The Associated Press

Monday, October 19, 2009

Print
Loading...

Biogen Idec Inc. and Biovitrum said Monday they will move a potential hemophilia B treatment into a late-stage study.

The global study is being designed to assess the safety and effectiveness of the drug candidate rFIXFc in preventing and treating bleeding associated with hemophilia B.

Shares of Biogen rose 31 cents to $49.51 in afternoon trading.

JOIN THE DISCUSSION
Rate Article:  Average 0 out of 5
Register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

New To Market

more

P2i showcases liquid repellent nano-coating for hearing aids
P2i showcases liquid repellent nano-coating for hearing aids

Mar 19

At the AudiologyNOW! 2010 show in San Diego next month, UK-based coatings company P2i will display their relatively new Aridion liquid-repellant nano-coating. Designed for exposure to humidity or sweat, the polymer layer is applied by a pulsed ion gas process that lower’s the hearing aid’s surface energy, coaxing water away from delicate components.

Submersible FlowCAM catches particle images and data in-situ and real-time

Mar 10

Fluid Imaging Technologies recently introduced its Submersible FlowCAM particle and cell imaging and analysis system at Ocean Sciences 2010 in Portland, Ore. The remote sensing platform can be used for continuous, unattended monitoring tethered to research vessels or autonomous submersibles.

Tools & Technology

more

Benchtop NMR analyzer
Benchtop NMR analyzer

Mar 18

Oxford Instruments America, Inc.’s Magnetic Resonance Group released the second generation of its MQC analyzers.

Software solution for microarray image analysis

Mar 18

BioDiscovery Inc. released ImaGene 9.0 for microarray image analysis. The new features include improved memory performance for the latest high density arrays, streamlined processing pipeline focused on image quantification and intensity extraction, and new modular design with options to add modules for analysis of gene/miRNA expression or CGH data.

Advertisement

Advertisement